MAP2K1 and RASopathy: Our data delineate qualitative differences in biological properties between cancer- and RASopathy-associated MEK1 mutants, and provide vital insights into the pathophysiology, diagnosis, and molecular basis for novel therapeutic strategies for these diseases.